Harrow Inc.: Strategic Acquisitions and Growth Prospects Impress H.C. Wainwright - Analyst Sees 84% Upside Potential!
Reading Time: 3 minutes
Harrow Inc. (HROW) stands out positively after the company presented robust fundamental data. In the second quarter of 2025, the company further strengthened its position as a leading provider of solutions for eye diseases in North America. The company’s comprehensive portfolio addresses a variety of eye conditions, including dry eyes, wet age-related macular degeneration (AMD), diabetic macular edema, cataracts, and glaucoma. By providing safe, effective, accessible, and affordable medications, Harrow aims to improve the standard of care. ...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
